Welcome to our dedicated page for Aardvark Therapeutics news (Ticker: AARD), a resource for investors and traders seeking the latest updates and insights on Aardvark Therapeutics stock.
Aardvark Therapeutics, Inc. (Nasdaq: AARD) is a clinical-stage biopharmaceutical company developing oral, small-molecule therapeutics for Prader-Willi Syndrome and metabolic diseases. The AARD news page on Stock Titan aggregates company press releases and third-party coverage so readers can follow how its pipeline and clinical programs evolve over time.
News about Aardvark frequently centers on clinical trial milestones, especially for ARD-101, its gut-restricted TAS2R agonist in Phase 3 development for hyperphagia associated with Prader-Willi Syndrome. Updates include protocol amendments aligned with the U.S. Food and Drug Administration, expansion of trial eligibility to younger pediatric patients, international site activations, and enrollment progress in the HERO pivotal trial and its Open Label Extension.
Investors and healthcare observers can also track pipeline developments for ARD-201, the planned fixed-dose combination of ARD-101 with a DPP-4 inhibitor, and WE-868, an isoflavonoid modulator of oxidative metabolism. Company releases highlight preclinical and clinical data presented at scientific meetings such as ObesityWeek, including findings on weight management, glucose control, lean mass preservation, and potential use after discontinuation of GLP-1 receptor agonist therapies.
Additional AARD news items cover financial results, investor events, and corporate actions, such as quarterly earnings press releases, participation in healthcare and cardiometabolic conferences, investor webinars, and inducement equity grants reported under Nasdaq Listing Rule 5635(c)(4). By reviewing this news feed, readers can see how Aardvark communicates its progress, interprets new data from its obesity and PWS programs, and reports on its operational and capital position.
For anyone monitoring biotechnology developments in PWS, metabolic obesity, and hunger-targeted therapies, the AARD news page offers a centralized view of Aardvark’s announcements and regulatory disclosures over time.
Aardvark Therapeutics (Nasdaq: AARD) announced inducement equity awards for six newly hired employees under its 2025 Inducement Equity Incentive Plan on February 9 and February 11, 2026.
Five employees received options for an aggregate 147,213 shares on February 9 at an exercise price of $13.48; one employee received 5,125 shares on February 11 at $12.67. Options vest over four years (25% after one year, then monthly 1/48th), with exercise prices equal to the closing share price on each grant date, and were granted as inducements under Nasdaq Listing Rule 5635(c)(4).
Aardvark Therapeutics (Nasdaq: AARD) announced on Feb 12, 2026 the creation of a wholly owned U.S. subsidiary, Ardia Therapeutics, to advance a dermatology pipeline led by DIA-615, a potential topical treatment for inflammatory skin diseases including psoriasis.
Bryan Jones, Ph.D., has been named CEO of Ardia and has transitioned from his role as Aardvark COO; management tenure and prior program experience were noted.
Aardvark Therapeutics (Nasdaq: AARD) announced leadership appointments effective February 9, 2026: Derrick C. Li named Chief Business Officer and Nelson Sun’s role expanded to Chief Operating Officer in addition to Chief Financial Officer.
The company said these moves coincide with continued development of ARD-201 (Phase 2) and with ARD-101 progressing to Phase 3, with topline Phase 3 data expected in Q3 2026.
Aardvark Therapeutics (Nasdaq: AARD) announced U.S. IRB approval and an FDA submission of an amended Phase 3 HERO trial protocol for lead candidate ARD-101, lowering minimum participant age from 10 to 7 years.
The amendment expands U.S. enrollment to younger children with Prader-Willi syndrome and the company says enrollment remains on track to report topline data in Q3 2026.
Aardvark Therapeutics (Nasdaq: AARD) announced dosing of the first patient in Australia in its Phase 3 HERO trial of ARD-101 for hyperphagia in Prader-Willi syndrome on Dec 10, 2025.
Regulatory clearance to enroll has been received for sites in Canada and the United Kingdom. US sites report strong enrollment and Australia sites began enrolling in November. All patients who completed the 12-week trial to date have entered the Open Label Extension. The company says the study is tracking toward a topline data readout in Q3 2026 and expects not to need previously planned EU sites to meet that timeline.
Aardvark Therapeutics (Nasdaq: AARD) will present at two investor conferences in December: Piper Sandler 37th Annual Healthcare Conference in New York on Wednesday, December 3, 2025 at 8:00 a.m. ET and Evercore ISI 8th Annual Healthcare Conference in Miami on Thursday, December 4, 2025 at 11:15 a.m. ET.
Live webcasts of each presentation will be accessible on the company investor website and an archived recording will be available there for approximately one month after each presentation.
Aardvark Therapeutics (Nasdaq: AARD) reported Q3 2025 results and pipeline updates on Nov 13, 2025. The company disclosed $126.4 million in cash, cash equivalents, and short-term investments as of Sept 30, 2025, which it expects will fund operations into 2027. Aardvark aligned with the FDA to lower the HERO Phase 3 ARD-101 trial minimum age from 13 to 10 years and started the HERO Open Label Extension with sites in Australia. Preclinical data for oral ARD-201 showed glucose control, lean mass preservation, ~19% weight reduction in mice, and ~30% weight loss when combined with low-dose tirzepatide. Topline HERO data expected Q3 2026; POWER interim data expected 2H 2026.
Aardvark Therapeutics (Nasdaq: AARD) announced an inducement equity award granted on November 10, 2025 to one new employee under its 2025 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The award is a stock option to purchase 4,881 shares of common stock with an exercise price equal to the closing price on the grant date, $10.44. The option vests over four years: 25% vest on the one-year anniversary of employment commencement and the remainder vests monthly at 1/48th thereafter, subject to continued employment.
Aardvark Therapeutics (Nasdaq: AARD) presented preclinical and clinical data at ObesityWeek 2025 supporting its metabolic obesity programs ARD-201, ARD-101 and WE-868.
Key highlights: ARD-201 (fixed-dose ARD-101 + sitagliptin) reduced fat mass comparable to high-dose tirzepatide while preserving lean mass, delivered glucose control comparable to high-dose tirzepatide, and previously showed ~19% weight reduction after 30 days and ~30% weight loss when combined with low-dose tirzepatide. ARD-101 showed signals of weight control, reduced hunger, and favorable tolerability in a Phase 2a study. WE-868 showed dose-dependent prevention of diet-induced weight gain in preclinical models.
Aardvark Therapeutics (Nasdaq: AARD) announced inducement equity option grants for new hires under Nasdaq Listing Rule 5635(c)(4).
The company granted options on three dates: Oct 20, 2025 (23,602 shares at $12.28), Oct 28, 2025 (aggregate 49,849 shares at $12.00), and Nov 3, 2025 (14,766 shares at $10.39), totaling 88,217 option shares. Each option’s exercise price equals the closing stock price on the grant date. Options vest over four years with 25% at the one-year anniversary and monthly vesting thereafter, subject to continued employment.
FAQ
What is the current stock price of Aardvark Therapeutics (AARD)?
What is the market cap of Aardvark Therapeutics (AARD)?
